Comparison of Efficacy and Safety Among Axitinib, Sunitinib, and Sorafenib As Neoadjuvant Therapy for Renal Cell Carcinoma: a Retrospective Study

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2019 Oct 12

PMID 31601263

Citations 6

Authors

Wen Cai

Biao Cai

Juan Zhou

Yonghui Chen

Jin Zhang

Yiran Huang

Wei Xue

Jiwei Huang

Affiliations

Soon will be listed here.

Citing Articles

Hypoxia-triggered ERRα acetylation enhanced its oncogenic role and promoted progression of renal cell carcinoma by coordinating autophagosome-lysosome fusion.

Feng C, Kong D, Tong B, Liang Y, Xu F, Yang Y Cell Death Dis. 2025; 16(1):23.

PMID: 39820331 PMC: 11739407. DOI: 10.1038/s41419-025-07345-1.

A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic -rearranged renal cell carcinoma:a case report.

Yang H, Dong X, Pan X, Ma W, Pan J, Guo H Front Oncol. 2023; 13:1252282.

PMID: 37936602 PMC: 10627181. DOI: 10.3389/fonc.2023.1252282.

[Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma].

Liu Y, Wu Z, Ge L, Du T, Wu Y, Song Y Beijing Da Xue Xue Bao Yi Xue Ban. 2023; 55(5):781-792.

PMID: 37807730 PMC: 10560895.

The elevated visceral adiposity index increases the risk of hyperuricemia in Chinese hypertensive patients: A cross-sectional study.

Liu H, Song X, Zhu J, Zhou W, Wang T, Yu C Front Endocrinol (Lausanne). 2023; 13:1038971.

PMID: 36589811 PMC: 9798281. DOI: 10.3389/fendo.2022.1038971.

Alternative splicing and alternative polyadenylation define tumor immune microenvironment and pharmacogenomic landscape in clear cell renal carcinoma.

Zhong W, Wu Y, Zhu M, Zhong H, Huang C, Lin Y Mol Ther Nucleic Acids. 2022; 27:927-946.

PMID: 35211354 PMC: 8829526. DOI: 10.1016/j.omtn.2022.01.014.

References

Lane B, Rini B, Novick A, Campbell S . Targeted molecular therapy for renal cell carcinoma. Urology. 2007; 69(1):3-10. DOI: 10.1016/j.urology.2006.09.028. View

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

Chapin B, Delacroix Jr S, Culp S, Nogueras Gonzalez G, Tannir N, Jonasch E . Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011; 60(5):964-71. PMC: 4378825. DOI: 10.1016/j.eururo.2011.05.032. View

Lane B, Derweesh I, Kim H, OMalley R, Klink J, Ercole C . Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol. 2014; 33(3):112.e15-21. DOI: 10.1016/j.urolonc.2014.11.009. View

Abel E, Culp S, Tannir N, Matin S, Tamboli P, Jonasch E . Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2010; 59(1):10-5. PMC: 4378833. DOI: 10.1016/j.eururo.2010.09.034. View

van der Veldt A, Meijerink M, van den Eertwegh A, Bex A, de Gast G, Haanen J . Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008; 14(8):2431-6. DOI: 10.1158/1078-0432.CCR-07-4089. View

Posadas E, Figlin R . Kidney cancer: progress and controversies in neoadjuvant therapy. Nat Rev Urol. 2014; 11(5):254-5. DOI: 10.1038/nrurol.2014.89. View

Karam J, Devine C, Urbauer D, Lozano M, Maity T, Ahrar K . Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014; 66(5):874-80. PMC: 4396847. DOI: 10.1016/j.eururo.2014.01.035. View

Hellenthal N, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding G . Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010; 184(3):859-64. PMC: 3105599. DOI: 10.1016/j.juro.2010.05.041. View

10.

Zhang Y, Li Y, Deng J, Ji Z, Yu H, Li H . Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma. PLoS One. 2015; 10(2):e0115896. PMC: 4315594. DOI: 10.1371/journal.pone.0115896. View

11.

Cai W, Kong W, Dong B, Zhang J, Chen Y, Xue W . Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma. Chin J Cancer. 2017; 36(1):64. PMC: 5547674. DOI: 10.1186/s40880-017-0230-7. View